concentration was similar in the two groups, ir-ET-1 concentration in thoracic aorta, mesenteric arterial Background. Elevated plasma and urine endothelin-1 ( ET-1) levels have been reported in renal failure and bed, renal cortex and urine was significantly lower in LU-treated animals (P<0.01). In addition, heart, thormay be involved in renal disease progression. We investigated whether these changes are related to acic aorta and mesenteric arterial wet weight to body weight ratios were also significantly reduced in LUincreased vascular and renal ET-1 production in the pole resection remnant kidney model of chronic renal treated uraemic rats (P<0.05).
controls. As expected, plasma and urine ir-ET-1 con-Introduction centrations were increased in uraemic rats (P<0.01) and were related to the increased ir-ET-1 levels in Endothelin-1 ( ET-1) appears to be involved in the blood vessels and glomeruli (P<0.01). Positive correlapathogenesis and progression of various renal diseases. tion was found between plasma, thoracic aorta and Increased urinary ET-1 excretion and plasma ET-1 mesenteric arterial bed ir-ET-1 levels and systolic blood levels have been reported in progressive and end-stage pressure, as well as blood vessel hypertrophy. In addirenal failure patients, and correlate with the deterioration, increased urinary ir-ET-1 excretion correlated tion of renal function and the elevation of blood with the rise in serum creatinine and proteinuria. In pressure [1] [2] [3] . These changes were recently attributed protocol 2, a 3-week treatment period with LU was to ET-1 overproduction in vascular and renal tissues initiated once uraemia and hypertension were estab- [4] [5] [6] [7] . ET-1 is mainly a local mediator, produced in lished. In untreated uraemic rats, systolic blood presvascular endothelial and glomerular mesangial cells, as sure increased further (P<0.05), but this was not the well as in tubular epithelial cells, and acts in an case in LU-treated uraemic rats. At the end of treatautocrine and paracrine fashion to modulate vascular ment, serum creatinine and proteinuria were significtone and extracellular volume [8, 9] . However, antly lower (P<0.05) and creatinine clearance was increased circulating ET-1 levels produce potent vasohigher (P<0.01) in LU-treated rats compared with constriction leading to systemic and renal haemouraemic-untreated animals. While plasma ir-ET-1 dynamic changes and hypertension [8, 10, 11] . In addition, ET-1 induces vascular smooth muscle and Correspondence and offprint requests to: R. Larivière, PhD, Centre mesangial cell growth as well as extracellular matrix with vascular remodelling, renal fibrosis and glomright kidney was removed. In protocol 1, a group of nephrecerulosclerosis.
tomized rats was compared with sham-operated animals used
The effects of ET-1 are mediated by two receptor as control. The animals were studied at week 8, i.e. 3 weeks subtypes, ET A and ET B , which have distinct pharmaco-after hypertension was established (systolic blood pressure logical and molecular characteristics as well as tissue >150 mmHg). In protocol 2, all animals underwent subtotal distribution [16] [17] [18] . ET A and ET B are members of nephrectomy. Similar to in protocol 1, once uraemia and the G-protein-coupled, seven-transmembrane-domain hypertension were established, at week 3, they were divided receptor family, both coupled to the phospholipase C into two groups with similar systolic blood pressure (180±11 signalling pathway. The ET A receptor is responsible and 172±7 mmHg, n.s. expressed in endothelial cells and mediates the release
The dose of LU utilized in this study was previously found of the endothelium-derived relaxing factor nitric oxide to effectively blunt the rise in blood pressure in the angio-(NO) and prostacyclin [19, 20] , which play an import-tensin-II-induced hypertension model [24] as well as the ant role in the normal compensatory vasorelaxation in erythropoietine-induced hypertension in this rat remnant response to ET-1. In the kidney, the ET A receptor kidney model of chronic renal failure [25] . Systolic blood predominantly controls the haemodynamic effects of pressure was measured by the tail-cuff method after warming ET-1, while the ET B receptor is involved in the tubular and with slight restriction using an IITC blood pressure system fitted with a Model 29 pulse sensor (IITC Life regulation of salt and water reabsorption [21] .
Science, Woodland Hills, CA, USA). Blood pressure readings
Recently, we [6, 7] and others [4, 5] reported were recorded and analysed using a computerized acquisition increased urinary ET-1 excretion due to overproducsystem (MP100, Biopac System, Goleta, CA, USA). The tion in preglomerular arteries and in glomeruli, in the average of three separate blood pressure readings was used renal artery branches ligation rat remnant kidney in the data analysis. At the end of each protocol, the animals model of chronic renal failure. Although plasma ET-1 were placed in metabolic cages and 24-h urine samples were level was normal in uraemic animals, ET-1 production collected and stored at −20°C for the assessment of protein, was significantly enhanced in blood vessels [6 ] . The sodium, creatinine and immunoreactive ET-1 (ir-ET-1) excrerapid progression of renal failure in this remnant tion. The animals were then anaesthetized with pentobarbital kidney model has been attributed to the activation of (50 mg/kg i.p.) and exsanguinated by abdominal aortic puncture. Blood samples were collected for the measurement of the renin-angiotensin system [22] . In fact, treatment haematocrit, serum creatinine and plasma ir-ET-1. The thorwith an angiotensin type 1 receptor antagonist normalacic aorta, segmented from the first to the eighth caudal ribs, ized blood pressure as well as proteinuria due in part and the complete mesenteric arterial bed, from the first to the reduction in vascular and renal ET-1 production cranial artery to the intestinal border, were removed and [7] . In the present study, we investigated ET-1 produc-cleaned of adipose tissue. Tissues were quickly frozen and tion in another rat remnant kidney model of chronic stored at −80°C for ir-ET-1 measurements. The heart was renal failure with pole resection, in which the renin-an-removed, cleaned of blood and weighed. Finally, the remnant giotensin system appears to be suppressed [22] . To kidney of uraemic rats and the kidneys of control animals confirm the role of ET-1 in the aggravation of were removed and dissected longitudinally. The papilla was hypertension and the progression of renal insuffici-discarded and the cortex was either immersed in 0.9% saline for immediate preparation of glomeruli (protocol 1) or cut ency in this model, one group of uraemic animals was into pieces of~100-50 mg, quickly frozen and stored at treated with the selective ET A receptor antagonist −80°C (protocol 2).
LU1325252 (LU ).

Preparation of glomeruli
Methods
Glomeruli were prepared as described previously [6, 7] . To obtain a sufficient amount of tissue for the assessment of ir-
Animal experiments
ET-1 concentration, kidneys harvested from two animals were utilized per group. Renal cortex was homogenized by Animal experiments, approved by the Laval University Animal Care Committee, were performed on 250 g male passage through a 0.4-mm stainless-steel grid. Tissues retained on the grid were washed with 0.9% saline solution, Wistar rats (Charles River Canada Inc., St-Constant, Quebec, Canada). The animals were allowed free access to standard minced with scissors and transferred onto a 150-mm mesh nylon sieve (Nitex, B & S.H. Thompson Co., Montreal, laboratory rat chow and tap water and were housed under controlled humidity, temperature and a 12 h light512 h dark Quebec, Canada). Tissues were pressed against the nylon sieve with a spatula to detach the remaining glomeruli and cycle. Renal mass reduction (5/6 nephrectomy) was performed by renal pole resection as described previously [23] . rinsed with saline solution. Glomeruli contained in the homogenate were isolated by filtration through 150, 50 and Briefly, the animals were anaesthetized with sodium pentobarbital (Somnotol, 50 mg/kg i.p.; MTC Pharmaceuticals, 100-mm mesh nylon sieves and washed with saline solution.
Glomeruli retained on the last sieve were transferred to a Cambridge, Ontario, Canada) and, via a flank incision, approximately two-thirds of the left kidney was removed by centrifugation tube and the average of three aliquots was used to determine the number of glomeruli under a lightexcision of the upper and lower poles. Blood loss was minimized by the application of gelatin sponges (Gelfoam, microscope. Preparations from control and uraemic rats ET A receptor blockade in uraemic rats 1883 contained <5% contamination with connective tissue and as with plasma ir-ET-1 levels ( Figure 1) . Moreover, tubules. Glomeruli were then collected by centrifugation at the increased urinary ir-ET-1 excretion correlated with 3000 g for 15 min at 4°C. Supernatants were removed, and the rise in serum creatinine and proteinuria (Figure the pellets were quickly frozen and stored at −80°C for the 2). This suggests that plasma and urinary ET-1 levels assessment of tissue ir-ET-1.
are associated with the aggravation of hypertension and the progression of renal insufficiency in this rat Measurement of ir-ET-1 in tissue, plasma and urine remnant kidney model. In fact, uraemic animals in protocol 2, which had a higher degree of renal failure One thoracic aorta, mesenteric arterial bed or preparation and hypertension compared with uraemic rats in protoof glomeruli was utilized per extraction tube and assayed col 1 (due to variability in surgical renal mass ablation), individually as described previously [6, 7] . Frozen tissues were were associated with greater plasma and urinary ET-1 weighed, homogenized with a Tissue-Tearor (Biospec levels ( Figures 1 and 2) .
Products, Bartlesville, OK, USA) three times for 15 s in 2 ml ice-cold extraction solution containing 1 N HCl, 1% acetic acid, 1% trifluoroacetic acid (TFA) and 1% NaCl. The Tissue ir-ET-1 concentration in uraemic rats homogenate was centrifuged at 3000 g for 30 min at 4°C. The supernatant was collected and extracted on a C 18
Sep-Compared with the controls, ir-ET-1 concentration in Pak column ( Waters, Milford, MA, USA). Similarly, plasma the thoracic aorta (P<0.05) and glomeruli (P<0.01) and urine samples (2 ml ) were acidified with 0.2% TFA, and was significantly higher in uraemic rats, whereas it was extracted on a C 18
Sep-Pak column as reported previously similar in the mesenteric arterial bed (Figure 3) . [3, 6 ] . Ir-ET-1 in the sample extracts was measured by a However, the total ir-ET-1 content in both the thorspecific radioimmunoassay, and the concentrations were cor-acic aorta and in the mesenteric arterial bed of rected for losses in the extraction and purification steps using uraemic rats was significantly higher (9.5±1.8 and small amounts of 125I-ET-1 (~1000 c.p.m.; DuPont NEN, 32±3 pg/vessel, respectively) compared with the conBoston, MA, USA). trols (3.6±0.1 and 22±3 pg/vessel, respectively; P<0.01). This may be attributed to hypertrophy of Other biochemical analysis vessels of uraemic rats since the thoracic aorta and mesenteric arterial bed wet weight to body weight Serum was obtained from 1-ml blood samples incubated for ratios were significantly greater in uraemic rats com-1 h at room temperature and centrifuged for 2 min in a pared with controls ( Table 3 , protocol 1); likewise, the bench-top microcentrifuge. Serum creatinine, as well as urinheart wet weight to body weight ratio was also signi- 3, prior to treatment, systolic blood pressure was significantly higher in uraemic rats (178±7 mmHg) compared with systolic blood pressure before renal
Results
mass ablation (120±5 mmHg; P<0.01). Systolic blood pressure in uraemic-untreated rats increased Systemic and renal parameters in uraemic rats significantly with time (P<0.05), whereas it did not change in LU-treated uraemic rats (Figure 4 ). Body weight was slightly, but significantly, lower in uraemic rats compared with sham-operated controls Body weight, haematocrit and plasma ir-ET-1 concentration were similar in untreated and LU-treated (P<0.05; Table 1 , protocol 1). In contrast, systolic blood pressure, serum creatinine and plasma ir-ET-1 uraemic rats ( Table 1 , protocol 2), whereas serum creatinine was significantly lower in LU-treated rats concentration were significantly higher (P<0.01), whereas haematocrit was lower in uraemic rats (P<0.01). In addition, proteinuria was lower (P<0.05) and creatinine clearance was higher (P<0.01) in LU-(P<0.01). In addition, urinary volume, protein and ir-ET-1 excretion were significantly greater in uraemic treated rats compared with uraemic-untreated rats ( Table 2, protocol 2) . Surprisingly, urinary volume rats compared with controls (P<0.01), whereas creatinine clearance was lower (P<0.01; Table 2 , protocol 1). was increased in LU-treated rats (P<0.01). Although urinary ir-ET-1 excretion tended to be lower in LUChanges in systolic blood pressure correlated positively with serum creatinine (r=0.709, P<0.01) as well treated rats, the difference did not reach statistical 
Discussion
In the present study, we reported that ir-ET-1 concentration is significantly increased in the blood vessels and glomeruli of rats with surgical renal mass ablation. These changes are similar to those observed in the renal artery branches ligation remnant kidney model [6, 7] . In addition, the increased urinary ET-1 excretion correlated with renal insufficiency, which was associated with greater ET-1 production in renal tissues, particularly in glomeruli. Furthermore, uraemic rats with pole resection have a higher plasma ir-ET-1 concentration. The latter observation contrasts to the former remnant kidney model, as well as chronic nondialysed uraemic patients, where plasma ir-ET-1 is unchanged [2,4,6,7]. Although one might attribute the higher plasma ET-1 levels to increased ET-1 production in blood vessels, tissue ir-ET-1 concentration in both remnant kidney models are similar [6, 7] . Thus, it may be postulated that plasma ET-1 clearance is altered in this remnant kidney model. Normally, locally produced ET-1 in vascular endothelial cells is released Fig. 1 . Correlation between changes in systolic blood pressure and on the abluminal side towards smooth muscle cells and immunoreactive endothelin-1 (irET-1) in plasma of control ($) and uraemic rats (%) in protocol 1 and uraemic-untreated rats (6) only small amounts of ET-1 reach the systemic circulain protocol 2.
tion [26 ] . ET-1 released into the blood stream is rapidly cleared from the circulation after passage through the significance. In contrast, ir-ET-1 concentration in the lungs [19] . However, it has been reported recently that thoracic aorta, the mesenteric arterial bed and the pulmonary ET-1 clearance is reduced in patients with renal cortex was significantly lower in LU-treated rats pulmonary hypertension, leading to a rise in plasma compared with uraemic-untreated animals (P<0.01; ET-1 [27] . Pulmonary hypertension also occurs in the Figure 5 ). This was associated with the significant pole resection rat remnant kidney model and may be reduction in wet weight to body weight ratios of vessels a contributing factor for the elevation of circulating ET-1 [28]. of LU-treated rats ( Table 3, The present findings that increased ET-1 levels in synthase [31] . This is consistent with the fact that -arginine supplementation in uraemic animals attenuvascular and renal tissues, as well as in the plasma of uraemic rats, correlated positively with blood pressure ates the rise in blood pressure and the progression of renal failure [32] . With respect to the renin-angiotensin and renal insufficiency support a role for ET-1 in the aggravation of hypertension and the progression of system, although plasma renin activity is suppressed in this rat remnant kidney model [22, 30] , angiotensinchronic renal failure. Since ET-1 is predominantly a local mediator, the elevated tissue ET-1 levels can converting enzyme inhibition normalizes blood pressure and significantly attenuates proteinuria [30] , cause powerful vasoconstriction leading to hypertension and renal haemodynamic changes [8, 10] . These suggesting that angiotensin II is also implicated in the pole resection model, similar to in the renal artery pathophysiological changes may also be related to the increased circulating ET-1 level. Indeed, Wilkins et al. branches ligation model [7] .
In this study, we also showed that increased vascular [11] have shown that a long-term, 2-fold rise in circulating ET-1 produces a significant elevation of blood ET-1 levels in uraemic rats were associated with greater wet weight to body weight ratio of blood vessels. In pressure associated with increased total peripheral and renal vascular resistance, and reduced glomerular fil-addition, blood vessel wet weight to body weight ratios were significantly reduced in LU-treated rats to levels tration rate. In the kidney, afferent and efferent arteriolar constriction in response to ET-1 reduces renal comparable with those in sham-operated animals, suggesting a role for ET-1 in vascular hypertrophy in blood flow and increases glomerular capillary pressure [10] , which may, in the long-term, contribute to glom-uraemia. This is consistent with our previous studies in hypertensive rats where increased ET-1 production erular injury.
The direct involvement of ET-1 in the present in blood vessels was associated with increased tissue wet weight and vascular media hypertrophy, which uraemic animal model was further confirmed by the fact that treatment with an ET A receptor antagonist were both significantly reduced by ET-1 receptor blockade [33] [34] [35] . ET-1 may contribute to vascular prevented the aggravation of hypertension and the progression of renal insufficiency. However, blood hypertrophy in uraemia through its potent effect on smooth muscle cell growth as well as its effect on extrapressure and renal parameters such as proteinuria were not reduced to normal values. This may be attributed, cellular matrix protein accumulation [12, 14] . A similar phenomenon probably occurs in the glomerulus to in part, to the unblocked ET B receptor, which can also mediate the vasoconstrictor response to ET-1 [29] . promote glomerulosclerosis [15, 36 ] . This is supported by the study of Orisio et al.
[5] documenting the relaHowever, blockade of both receptor subtypes with the ET A /ET B antagonist bosentan causes a similar blood tionship between increased renal ET-1 production and glomerulosclerosis in rats with reduced renal mass. In pressure lowering effect and attenuation of the progression of renal insufficiency as with ET A receptor block-addition, ET-1 receptor blockade has been shown to prevent glomerulosclerosis in remnant kidneys [30, 37] . ade [25, 30] . Thus, other mechanisms, not affected by ET-1 receptor blockade, must be involved in the main-Thus, the ET A receptor antagonism with LU may also cause protective effects by attenuating vascular hypertenance of hypertension and renal disease progression. These may include impaired vasorelaxing effect of the trophy and remodelling, and glomerular damage.
The mechanisms leading to enhanced ET-1 producendothelium-derived relaxing factor NO. In fact, NO release appears to be reduced in uraemia, due in part tion in uraemic animals are not completely understood.
Recently, we reported that angiotensin II is an importo the accumulation in plasma of asymmetrical dimethylarginine, an endogenous inhibitor of NO tant modulator of ET-1 production in blood vessels ) receptor antagonist LU135252 (LU ) on systolic blood pressure in uraemic rats. Treatment with LU (50 mg/kg/day) was initiated once uraemia and hypertension were established, at week 3, for 3 weeks. Nx, time point of subtotal (5/6) nephrectomy. *P<0.05 systolic blood pressure in untreated uraemic rats at weeks 3 and 6; **P<0.01 vs LUtreated uraemic rats at the same time point.
and glomeruli [7] . In fact, the protective effects of angiotensin type 1 receptor antagonism or angiotensinconverting enzyme inhibition were related in part to the significant reduction in ET-1 production in vascular and renal tissues [7] . This is consistent with the fact that angiotensin II is a potent stimulator of ET-1 production and release in vascular endothelial cells as well as in glomerular mesangial cells [15, 38] . Since angiotensin-converting enzyme inhibition also significantly reduces blood pressure and proteinuria in this remnant kidney model [30] , it is highly likely that ET-1 production is modulated by angiotensin II. In addi- positively with blood pressure suggests that haemodynamic changes may also modulate ET-1 production. induces NO release from endothelial cells, which inhibits ET-1 production [19, 20] . In this study, we documented that ET A receptor blockade significantly reduced both ET-1 levels in blood vessels and renal tissues, as well as ET-1 excretion in uraemic animals. The mechanisms underlying this phenomenon remain unknown. However, it can be postulated that the reduction in blood pressure and, possibly, the haemodynamic shear stress may attenuate ET-1 production. This may also be related to ET B -induced NO release from the endothelial cells, which inhibit both the vasopressor effect and the local production of ET-1 [19, 20] . In addition, it has been reported that the ET B receptor subtype is also involved in the clearance of ET-1 [43] . Thus, unblocked ET B receptor can contribute to reduce the tissue ET-1 level in uraemic animals. In contrast, it is unlikely that ET A receptor blockade directly affects ET-1 level. In fact, ET-1 can stimulate its own production in endothelial cells as well as in mesangial cells via the ET B receptor activation, but not the ET A receptor [44, 45] . However, ET A receptor blockade may reduce ET-1 levels through the attenuation of ET-1-induced production of growth factors such as transforming growth factor ( TGF )-b [46 ], a potent stimulator of ET-1 production in endothelial and mesangial cells [38, 47] .
In summary, increased ET-1 levels in the plasma and urine of uraemic rats with surgical renal mass ablation are related to enhanced ET-1 production in blood vessels and glomeruli. The protective effects of treatment with the selective ET A receptor antagonist LU135252 confirms the role of ET-1 in the aggravation of hypertension and the progression of renal insufficiency in this rat remnant kidney model of chronic renal failure. 
